PlainRecalls
FDA Devices Moderate Class II Terminated

ETEST IMIPENEM RELEBACTAM. in vitro diagnostic

Reported: August 18, 2021 Initiated: June 24, 2021 #Z-2226-2021

Product Description

ETEST IMIPENEM RELEBACTAM. in vitro diagnostic

Reason for Recall

Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.

Details

Recalling Firm
Biomerieux Inc
Units Affected
1,431
Distribution
Worldwide distribution - US Nationwide distribution including in the states of AR, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, MA, MD, ME, MI, MN, MO, NC, NE, NH, NJ, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WA, WI, WV and Hawaii. The countries of Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.
Location
Hazelwood, MO

Frequently Asked Questions

What product was recalled?
ETEST IMIPENEM RELEBACTAM. in vitro diagnostic. Recalled by Biomerieux Inc. Units affected: 1,431.
Why was this product recalled?
Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.
Which agency issued this recall?
This recall was issued by the FDA Devices on August 18, 2021. Severity: Moderate. Recall number: Z-2226-2021.